# Mandatory Guidelines for Federal Workplace Drug Testing Programs—Authorized Testing Panels
**AGENCY:**
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS).
**ACTION:**
Issuance of authorized drug testing panels.
**SUMMARY:**
HHS herein publishes the panels of Schedule I and II drugs and biomarkers authorized for testing in federal workplace drug testing programs. The Department has made no revisions to the current drug testing panels for both urine and oral fluid and current required nomenclature for laboratory and Medical Review Officer Reports, effective July 7, 2025.
**DATES:**
The current authorized drug testing panels and required report nomenclature remain in effect.
**FOR FURTHER INFORMATION CONTACT:**
Eugene D. Hayes, Ph.D., MBA, SAMHSA, Center for Substance Abuse Prevention, Division of Workplace Programs; 5600 Fishers Lane, Room 16N02, Rockville, MD 20857, by telephone (240) 276-1459 or by email at *[email protected].*
**SUPPLEMENTARY INFORMATION:**
The drug testing panels in this notification specify the analytes and cutoffs for federal agency workplace drug testing specimens and the nomenclature ( *i.e.,* analyte names and abbreviations) that
must be used to report federal workplace drug test results. There are no changes to the drug testing analytes, test cutoffs, and report nomenclature published in the January 16, 2025, Notification (90 FR 4662). The Department has edited footnotes 1 and 2 in the drug testing panels for clarity and correctness.
This notification is in accordance with Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG, 88 FR 70768) and the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG, 88 FR 70814). Section 3.4 of Subpart C calls upon the Secretary of HHS to “publish the drug and biomarker test analytes and cutoffs ( *i.e.,* the `drug testing panel' and `biomarker testing panel') for initial and confirmatory drug and biomarker tests in the *Federal Register* each year,” and make them available on the internet at *http://www.samhsa.gov/workplace.* Section 3.4 of the UrMG and the OFMG also requires HHS-certified laboratories, instrumented initial test facilities (IITF, urine only), and Medical Review Officers to use the nomenclature ( *i.e.,* analyte names and abbreviations) published with the drug and biomarker testing panels to report federal workplace drug test results.
**Costs and Benefits**
No analysis is needed because the current drug testing panels and nomenclature tables remain in effect. Currently, the Department does not require HHS-certified test facilities to implement authorized biomarker tests. Each laboratory and IITF should conduct their own cost analysis when deciding whether to offer biomarker testing to federally regulated clients. The Department will consider costs when deciding whether to require all certified test facilities to test for a specific biomarker.
| Urine | Abbreviation | Analyte |
| --- | --- | --- |
| Δ9THCC | Δ-9-tetrahydrocannabinol-9-carboxylic acid. | |
| BZE | Benzoylecgonine. | |
| COD | Codeine. | |
| MOR | Morphine. | |
| HYC | Hydrocodone. | |
| HYM | Hydromorphone. | |
| OXYC | Oxycodone. | |
| OXYM | Oxymorphone. | |
| 6-AM | 6-Acetylmorphine. | |
| PCP | Phencyclidine. | |
| FENT | Fentanyl. | |
| NFENT | Norfentanyl. | |
| AMP | Amphetamine. | |
| MAMP | Methamphetamine. | |
| MDMA | Methylenedioxymethamphetamine. | |
| MDA | Methylenedioxyamphetamine. | |
| HHS Drug Testing Panel—Urine | Initial test analyte | Initial test | Confirmatory test analyte | Confirmatory test cutoff |
| --- | --- | --- | --- | --- |
| Marijuana metabolite (Δ9THCC) | 50 | Δ9THCC | 15 | |
| Cocaine metabolite (Benzoylecgonine) | 150 | Benzoylecgonine | 100 | |
| Codeine/Morphine | 2,000 | Codeine | 2,000 | |
| | | Morphine | 4,000 | |
| Hydrocodone/Hydromorphone | 300 | Hydrocodone | 100 | |
| | | Hydromorphone | 100 | |
| Oxycodone/Oxymorphone | 100 | Oxycodone | 100 | |
| | | Oxymorphone | 100 | |
| 6-Acetylmorphine | 10 | 6-Acetylmorphine | 10 | |
| Phencyclidine | 25 | Phencyclidine | 25 | |
| Fentanyl | 1 | Fentanyl | 1 | |
| | | Norfentanyl | 1 | |
| Amphetamine/Methamphetamine | 500 | Amphetamine | 250 | |
| | | Methamphetamine | 250 | |
| MDMA/MDA | 500 | Methylenedioxymethamphetamine | 250 | |
| | | Methylenedioxyamphetamine | 250 | |
**HHS Biomarker Testing Panel—Urine**
SAMHSA has not yet authorized routine testing for any biomarker in urine. HHS-certified laboratories and IITFs may request authorization to test federal agency specimens for a biomarker upon Medical Review Officer request by submitting supporting documentation and assay validation records to the National Laboratory Certification Program for SAMHSA review and approval.
| Oral fluid | Abbreviation | Analyte |
| --- | --- | --- |
| Δ9THC | Δ-9-tetrahydrocannabinol. | |
| COC | Cocaine. | |
| BZE | Benzoylecgonine. | |
| COD | Codeine. | |
| MOR | Morphine. | |
| HYC | Hydrocodone. | |
| HYM | Hydromorphone. | |
| OXYC | Oxycodone. | |
| OXYM | Oxymorphone. | |
| 6-AM | 6-Acetylmorphine. | |
| PCP | Phencyclidine. | |
| FENT | Fentanyl. | |
| AMP | Amphetamine. | |
| MAMP | Methamphetamine. | |
| MDMA | Methylenedioxymethamphetamine. | |
| MDA | Methylenedioxyamphetamine. | |
| HHS drug testing panel—undiluted (neat) oral fluid | Initial test analyte | Initial test | Confirmatory test analyte | Confirmatory |
| --- | --- | --- | --- | --- |
| Marijuana (Δ9THC) | 4 | Δ9THC | 2 | |
| Cocaine/Benzoylecgonine | 15 | Cocaine | 8 | |
| Codeine/Morphine | 30 | Codeine | 15 | |
| Hydrocodone/Hydromorphone | 30 | Hydrocodone | 15 | |
| Oxycodone/Oxymorphone | 30 | Oxycodone | 15 | |
| 6-Acetylmorphine | 4 | 6-Acetylmorphine | 2 | |
| Phencyclidine | 10 | Phencyclidine | 10 | |
| Fentanyl | 4 | Fentanyl | 1 | |
| Amphetamine/Methamphetamine | 50 | Amphetamine | 25 | |
| MDMA/MDA | 50 | Methylenedioxymethamphetamine | 25 | |
**HHS Biomarker Testing Panel—Oral Fluid**
SAMHSA has not yet authorized routine testing for any biomarker in oral fluid. HHS-certified laboratories may request authorization to test Federal agency specimens for a biomarker by submitting supporting documentation and assay validation records to the National Laboratory Certification Program for SAMHSA review and approval. Authorized biomarker test cutoffs for oral fluid will be based on undiluted (neat) oral fluid.
Robert F. Kennedy, Jr.,
Secretary, Department of Health and Human Services.